Dana-Farber/Harvard Cancer Center

Dana-Farber/Harvard Cancer Center
Name	Dana-Farber/Harvard Cancer Center
Location	Boston, Massachusetts
Established	1991
Type	Cancer research consortium
Affiliations	Harvard Medical School; Brigham and Women's Hospital; Children's Hospital Boston; Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Dana-Farber/Harvard Cancer Center is a National Cancer Institute–designated comprehensive cancer center based in Boston, Massachusetts that integrates research, clinical care, and education across multiple Harvard-affiliated institutions. The center serves as a hub linking investigators from Harvard Medical School, Dana–Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital to translate discoveries into therapies. It participates in national consortia and collaborates with international partners to advance oncology science and patient outcomes.

History

The center was formally designated by the National Cancer Institute in the early 1990s, building on legacies from institutions including Dana–Farber Cancer Institute and research programs with roots in postwar biomedical expansion tied to figures such as Sidney Farber and linked to institutions like Harvard School of Public Health and Massachusetts Institute of Technology. Early cooperative efforts drew investigators from Massachusetts Eye and Ear, Joslin Diabetes Center, McLean Hospital, and Tufts Medical Center to form multidisciplinary teams focused on translational oncology. Over subsequent decades, the center expanded programs in molecular oncology, clinical trials, and population science through partnerships with Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, MD Anderson Cancer Center, University of California, San Francisco, and international collaborators such as Institute Gustave Roussy and Institut Curie.

Organization and Affiliations

Organizationally, the center is an alliance of Harvard-affiliated hospitals and research institutes including Dana–Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital. It maintains administrative ties to Harvard Medical School and coordinates cores shared with centers such as Broad Institute and Whitehead Institute. Leadership has included investigators with appointments at institutions like Harvard School of Public Health, Sloan Kettering Institute, and Cold Spring Harbor Laboratory. The center is a member of collaborative networks including the Cancer Center Support Grant system, participates in cooperative groups like Alliance for Clinical Trials in Oncology and SWOG, and collaborates with foundations including American Cancer Society, St. Baldrick's Foundation, and Conquer Cancer Foundation.

Research Programs and Initiatives

Research spans basic, translational, and clinical domains through programs in areas such as molecular oncology, immunotherapy, cancer genomics, pediatric oncology, and cancer prevention. Major initiatives have linked investigators to projects with The Cancer Genome Atlas, Human Genome Project, and consortia like Pediatric Oncology Group and Children's Oncology Group. Programs include precision oncology efforts that integrate technologies from institutions like Broad Institute and Whitehead Institute, immuno-oncology trials informed by work at Institute of Cancer Research and Memorial Sloan Kettering Cancer Center, and population studies drawing on cohorts such as Nurses' Health Study and Health Professionals Follow-up Study. Translational platforms support biomarker development alongside collaborations with industry partners including Genentech, Pfizer, AstraZeneca, Novartis, Merck & Co., Roche, Bristol-Myers Squibb, and biotech firms spun out from Harvard Faculty of Arts and Sciences laboratories.

Clinical Care and Patient Services

Clinical activities are delivered through affiliated hospitals—Dana–Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital—offering multidisciplinary care in medical oncology, radiation oncology, surgical oncology, and supportive services. Clinical trials are run in partnership with cooperative groups like NCI Cancer Therapy Evaluation Program and international trial networks such as European Organisation for Research and Treatment of Cancer. Patient navigation, palliative care, survivorship programs, and psychosocial support coordinate with community organizations including American Cancer Society and patient advocacy groups like Livestrong Foundation, Susan G. Komen, and St. Jude Children's Research Hospital for pediatric transitions.

Education and Training

The center hosts training for trainees from Harvard Medical School, postdoctoral fellows from programs linked to Broad Institute and Whitehead Institute, and residency rotations in oncology at Massachusetts General Hospital and Brigham and Women's Hospital. Educational efforts include career development awards modeled on mechanisms from National Institutes of Health and structured curricula connected to Harvard T.H. Chan School of Public Health, and joint seminars with institutions such as MIT, Tufts University, and Boston University. Mentorship networks engage faculty awarded honors like the Lasker Award, National Medal of Science, and MacArthur Fellowship to attract early-career investigators.

Funding and Grants

Funding sources include the National Cancer Institute Cancer Center Support Grant, competitive awards from the National Institutes of Health, foundation grants from Howard Hughes Medical Institute, private philanthropy from entities such as Dana Foundation and major donors linked to Jimmy Fund, industry-sponsored trials supported by Genentech and Merck & Co., and collaborative grants with organizations like Bill & Melinda Gates Foundation and Wellcome Trust. The center administers pilot grants, program project grants modeled after P01 grants and training grants similar to T32 grants to sustain translational pipelines.

Notable Achievements and Awards

Notable achievements include contributions to targeted therapies informed by discoveries related to genes cataloged in The Cancer Genome Atlas, advances in immunotherapy paralleling breakthroughs celebrated by the Nobel Prize in Physiology or Medicine winners whose work intersects checkpoint blockade, influential clinical trials that shaped standards of care cited by organizations like American Society of Clinical Oncology, and recognition through prestigious awards such as NIH Director's Pioneer Award and institutional honors from Harvard University. Faculty and trainees have received accolades including the Lasker Award, MacArthur Fellowship, National Medal of Science, and election to the National Academy of Sciences and American Academy of Arts and Sciences.

Category:Cancer research institutes